PPT-Robert Plenge, MD, PhD The Role of Human Genetics in Drug Discovery

Why do drugs fails now it is efficacysafety It was pharmacokinetics Human genetics helps to identify potential drug targets to start drug discovery Disease Healthy The key steps are M. By Andreas Dr Lorenz M.Mayr Drug Discovery World Summer 2006 Miniaturisation ofassay developmentand screening In recent years we have seen a strong increase in the number of chemicalcompounds and mole an Industrial Process. How are drugs . discovered and developed?. Dr Steve Carney, s.carney@elsevier.com. Managing Editor, . Drug Discovery Today. What’s my background?. First degree in Biochemistry. – . get ready for the show. Weidong Zhang. Pfizer. 1. Outline. Overview of omics technology. Application of omics in drug discovery. Case studies from pre-clinical to phase II/III. 2. 3. Omics provide paramount view of biological cascade. Properties: . Optimizing Pharmacokinetics and Safety During Drug . Discovery. ACS Short Course. Li Di and Edward H. Kerns. Introduction to Drug-Like Properties. Few research compounds will become drugs because they lack sufficient pharmacokinetics (PK) and safety. Distinguished University Professor Lecture. Presented on January 29, 2015 by Paul Erhardt, PhD. UT DUP and Director of the Center for Drug Design and Development (CD3). paul.erhardt@utoledo.edu. 1. Outline. Behavior Genetics: . Predicting Individual Differences. The topics in the text:. genes. twin and adoption studies . temperament and heredity. molecular genetics. heritability. gene/environment interaction. Please Sign Up:. . Name. . Email (. Onyen. is fine, or …). . Are You . ENRolled. ?. Dept. & Advisor (Lab?). . Tentative Title (“????” Is OK). . When:. Next Week, Early, Oct., Nov., Late. the future is now. Robert Plenge, MD, PhD. Broad Institute. Medical and Population Genetics (MPG). October 1, 2015. The Problem. http://. csdd.tufts.edu. /. Phase II/III failures drive high cost of drug development. Gerald J. Wyckoff. Training modes. Are we training . genomicists. to deal with the right problems?. Are the training modalities we’re using proper?. What questions should we be looking at?. Problems in Drug Discovery. Lectures. . – . 17x2 (Med); . 17x1. (. Stom. ). ;. Seminars. – . 17x3 (Med); . 17x2. (. Stom. ). ;. 3 . concluding . tests. (. tests. + . practical part. ). Final . examination . (. tests. + . linking diseases, drivers, targets and drugs. via multi-omics, clinical, imaging and perturbation data fusion. Nathalie Pochet, Ph.D.. Assistant Professor, Harvard Medical School. Associate Scientist, Brigham and Women’s Hospital. Functional Applications of Human Genetics and Genomics Commissioned by the American Society of Human Genetics Produced by TEConomy Partners, LLC. Report Authors: Simon Tripp and Martin Grueber May 2 electrospray. ionization a variety of LC/MS applications for the pharmaceutical industry have been developed for compound identification and quantification.. LC/MS is suitable for many applications, from pharmaceutical development to environmental analysis. Its ability to detect a wide range of compounds with great sensitivity and . 1. Dr. Abd El Raheim Donia. Generally,. . a drug . can be . defined . as a . substance that . induces . a response . within the human . body.. Dr. Abd El Raheim Donia. 2. FDA Definition . of a . Drug.